scout

Emory vs. Vanderbilt FACE-OFF: Novel Therapies Demonstrate Efficacy in Relapsed/Refractory Hematologic Malignancies

EP. 2: First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

ByAshwin Kishtagari, MD,Vivek Govind Patel, MD,Nisha Joseph, MD,Martha Arellano, MD ,Colin Vale, MD

Experts provide the first report of results from the Phase 3 PhALLCON trial comparing initial therapy with ponatinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

EP. 3: Consolidation Therapy With Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients With B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results From ECOG-ACRIN E1910

ByAshwin Kishtagari, MD,Vivek Govind Patel, MD,Nisha Joseph, MD,Martha Arellano, MD ,Colin Vale, MD

Experts present findings on blinatumomab consolidation therapy from the Phase 3 ECOG-ACRIN E1910 trial in adult patients with newly diagnosed B-lineage acute lymphoblastic leukemia who achieved measurable residual disease-negative remission.

EP. 4: Frontline Combination of Ponatinib and Hyper-CVAD in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: 80-Months Follow-up Results

ByAshwin Kishtagari, MD,Vivek Govind Patel, MD,Nisha Joseph, MD,Martha Arellano, MD ,Colin Vale, MD

Experts provide extended follow-up on efficacy and safety outcomes with initial therapy combining ponatinib and hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us